Onglyza, Velcade, Tyverb to win EU extensions
This article was originally published in Scrip
GlaxoSmithKline, Janssen and Bristol-Myers Squibb/AstraZeneca look set to win extensions for Tyverb (lapatinib), Velcade (bortezomib) and Onglyza (saxagliptin) respectively after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave them the green light last week. The committee's positive opinions now need to be formally approved by the European Commission.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.